Skip to main content

Table 2 Clinicopathological characteristics of HCC patients (n = 21)

From: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma

Clinical Characteristics Variables Available data (n) n (%)
Age, years 20–30/30–40/40–50/50–60/60–70/ > 70 21 2(9.52%)/2(9.52%)/7(33.3%)/5(23.8%)/4(19.0%)/5(23.8%)
Gender Male/Female 21 18(85.7%)/3(14.3%)
TNM T1bN0M0/T2N0M0/T4N0M0/T4N1M1 11 6(54.5%)/1(9.0%)/3(27.3%)/1(9.0%)
BCLC 0/A/B/C 14 1(7.1%)/7(50.0%)/2(14.3%)/4(28.6%)
Immunohistochemistry GPC3(+)/ GPC3(−) 13 7(53.8%)/6(46.2%)
Hep-1(+)/ Hep-1(−)/None 18 11(61.1%)/1(5.5%)/6(33.3%)
CD34(+)/CD34(−)/None 18 10(55.6%)/2(11.1%)/6(33.3%)
HBsAg(+)/HBsAg(−) 18 14(77.8%)/4(22.2%)
Arginase(+)/Arginase(−)/None 18 8(44.4%)/1(5.5%)/9(50.0%)
AMACR(+)/AMACR(−)/None 18 8(44.4%)/5(27.8%)/5(27.8%)
CK7(+)/CK7(−) 18 1(5.5%)/17(94.4%)
GS(+)/GS(−) 18 2(11.1%)/16(88.9%)
HSP70(+)/HSP70(−) 18 11(61.1%)/7(38.9%)
CD10(+)/CD10(−) 18 2(11.1%)/16(88.9%)
CK19(+)/CK19(−) 18 1(5.5%)/17(94.4%)
CD31(+)/None 18 9(50.0%)/9(50.0%)
\